Home > Specialties > Reagents, Immunoassay, Autoimmune, Antineutrophil Cytoplasmic Antibody, Proteinase 3

Reagents, Immunoassay, Autoimmune, Antineutrophil Cytoplasmic Antibody, Proteinase 3

Definition : Immunoassay reagents intended to perform qualitative and/or quantitative analyses on a body fluid sample (e.g., serum) to determine antineutrophil cytoplasmic antibodies to proteinase 3 (PR3-ANCA). Increased circulating levels of PR3-ANCA are used in the diagnostic of systemic vasculitis, they are also associated with extra-renal organ involvement (especially respiratory involvements), autoimmune connective tissue diseases, and Wegener's granulomatosis. Most patients identified with cytoplasmic-ANCA using indirect immunofluorescence, a less specific method, have antibodies to PR3-ANCA.

Entry Terms : "Proteinase 3 Antineutrophil Cytoplasmic Antibody (PR3-ANCA) Determination Reagents" , "Proteinase 3 (PR3) Determination Reagents" , "PR3-ANCA Determination Reagents" , "PR3-ANCA (Proteinase 3 Antineutrophil Cytoplasmic Antibody) Determination Reagents"

UMDC code : 20113


1-4 of 4 Match(es).

Diamedix Corp

Diamedix Corporation and its forerunner, Cordis Laboratories, have been on the leading edge of medical diagnostic technologies for more than a quarter century. Throughout the years, Diamedix has continued to pioneer unique immunodiagnostic innovations in its products, procedures, and in the development of integrated instrument and reagent systems for both autoimmune and infectious disease detection. Today, Diamedix maintains its tradition of developing product systems designed specifically to simplify and improve diagnostic testing in ways that enhance efficiency and accuracy, while promoting economy.

EUROIMMUN Medical Diagnostics Canada Inc

EUROIMMUN Medical Diagnostics Canada Inc

Hemagen Diagnostics Inc

Hemagen Inc. was founded in 1985 by a group of scientists from the Boston University School of Medicine.

Zeus Scientific Inc

ZEUS Scientific is a privately held corporation that was founded in 1976. The company began producing IFA (immunofluorescence assay) test systems followed ELISA and now multiplex (AtheNA Multi-Lyte) immunoassays. New products are developed to expand the menu which allows laboratories to run an increasing number of assays with common protocols and common reagents, as well as developing new tests to more accurately diagnose patients. In 1987 ZEUS Scientific was the first company to develop, receive appropriate regulatory clearance and bring to market a serological assay to test for Lyme disease – a condition with high prevalence in the local community where ZEUS Scientific is located.

1-4 of 4 Match(es).


Medical Product Guide Optometric Management Product Guide